InvestorsHub Logo
Followers 48
Posts 5518
Boards Moderated 0
Alias Born 09/04/2009

Re: Atom0aks post# 223942

Saturday, 11/09/2019 6:43:47 PM

Saturday, November 09, 2019 6:43:47 PM

Post# of 426447
"due to the potentially large population in contrast to the modest benefit"? 12% RRR for Vascepa on primary prevention doubles that of 6% RRR for Ezetimibe. Last time I check, Ezetimibe is still on the AHA/ACC guidelines. A 12% RRR applied across a larger population is going to reduce lots of MACE and improve the health and well being of citizens in this country. Do you know ICER has already determined that Vascepa is one of the most cost effective drug ever reviewed? Why you worry about the cost so much and ignore the societal benefits that Vascepa could bring?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News